What front line therapy would you recommend for a patient with CLL on chronic dual antiplatelet therapy?
How would your choice of therapy differ (if at all) for high vs low risk disease?
Would the specific anti-platelet agents used influence your choice above?
Are there any circumstances where you would give a BTK inhibitor with concurrent dual anti-platelet therapy?
Community PollStarted
What front line therapy would you recommend for a patient with CLL (without del(17p)/TP53) on chronic dual antiplatelet therapy?
62 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Medical Oncology · Mayo Clinic
Answered on
Given the bleeding risks associated with BTKi, I personally may prefer venetoclax-based therapy if feasible, in treating patients who require dual antiplatelet therapy (DAPT). This is based on safety considerations.
I consider both BTKi-based therapy and venetoclax-based therapy great options for fr...
Join for free or sign in to see the full answer